Table 2.

Efficacy of sgp130Fc-mediated blockade of interleukin-6 (IL-6) trans-signaling in preclinical models of inflammation and inflammation-associated cancer

Intestinal inflammation (Atreya et al. 2000; Mitsuyama et al. 2006)	Pancreatic cancer (Lesina et al. 2011)	Ovarian hyperstimulation (Wei et al. 2013)
Rheumatoid arthritis (Nowell et al. 2003, 2009; Richards et al. 2006)	Acute inflammation (Chalaris et al. 2007; Rabe et al. 2008)	Lupus erythematosus (Tsantikos et al. 2013)
Asthma (Doganci et al. 2005)	Sepsis (Barkhausen et al. 2011; Greenhill et al. 2011)	Nephrotoxic nephritis (Luig et al. 2015; Braun et al. 2016)
Colon cancer (Grivennikov et al. 2009; Matsumoto et al. 2010)	Arterosclerosis (Schuett et al. 2012)	Lung cancer (Brooks et al. 2016)
Ovarian cancer (Greenhill et al. 2011; Lo et al. 2011)	Pancreatitis-lung failure (Zhang et al. 2013)	Lung emphysema (Ruwanpura et al. 2016)